The Company intends to produce products that will include the following medicinal cannabis products: transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and possibly salves, creams, gels, lotions, and liquid extracts.
The registrant is currently working with physicians, scientists, engineers and other professionals to formulate a wide range of product delivery systems to assure our products are a precise and safe alternative as a potential treatment for chronic illness. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent disease.
Through our strategic partnership, the Company plans to launch our first series of products in 2016. In the coming months, we plan to expand our product line to include targeted treatment patches.